Scarica l'app Stockscreener
47.77
0.53%
0.275
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Sanofi Adr Borsa (SNY) Ultime notizie
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS
Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz
The Truth About Sanofi S.A.: Is This ‘Boring’ Pharma Stock a Secret Power Play? - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Regeneron Just Moved From Underperform To Buy - Benzinga
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz
Where is Sanofi (SNY) Headed According to Wall Street? - Finviz
Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz
Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm
Our Environmental Impact - Sanofi
Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):